JP2017534618A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534618A5 JP2017534618A5 JP2017521988A JP2017521988A JP2017534618A5 JP 2017534618 A5 JP2017534618 A5 JP 2017534618A5 JP 2017521988 A JP2017521988 A JP 2017521988A JP 2017521988 A JP2017521988 A JP 2017521988A JP 2017534618 A5 JP2017534618 A5 JP 2017534618A5
- Authority
- JP
- Japan
- Prior art keywords
- criteria
- sirs
- terlipressin
- treatment
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019155678A JP6989571B2 (ja) | 2014-10-24 | 2019-08-28 | １型肝腎症候群患者の治療方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462068357P | 2014-10-24 | 2014-10-24 | |
| US62/068,357 | 2014-10-24 | ||
| US201562151384P | 2015-04-22 | 2015-04-22 | |
| US62/151,384 | 2015-04-22 | ||
| PCT/US2015/056861 WO2016065117A1 (en) | 2014-10-24 | 2015-10-22 | Method of treating patients with hepatorenal syndrome type 1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019155678A Division JP6989571B2 (ja) | 2014-10-24 | 2019-08-28 | １型肝腎症候群患者の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017534618A JP2017534618A (ja) | 2017-11-24 |
| JP2017534618A5 true JP2017534618A5 (enExample) | 2018-09-27 |
| JP6673915B2 JP6673915B2 (ja) | 2020-03-25 |
Family
ID=54478246
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017521988A Active JP6673915B2 (ja) | 2014-10-24 | 2015-10-22 | １型肝腎症候群患者の治療方法 |
| JP2019155678A Active JP6989571B2 (ja) | 2014-10-24 | 2019-08-28 | １型肝腎症候群患者の治療方法 |
| JP2021102221A Active JP7346494B2 (ja) | 2014-10-24 | 2021-06-21 | １型肝腎症候群患者の治療方法 |
| JP2022146052A Withdrawn JP2022171795A (ja) | 2014-10-24 | 2022-09-14 | １型肝腎症候群患者の治療方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019155678A Active JP6989571B2 (ja) | 2014-10-24 | 2019-08-28 | １型肝腎症候群患者の治療方法 |
| JP2021102221A Active JP7346494B2 (ja) | 2014-10-24 | 2021-06-21 | １型肝腎症候群患者の治療方法 |
| JP2022146052A Withdrawn JP2022171795A (ja) | 2014-10-24 | 2022-09-14 | １型肝腎症候群患者の治療方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10335452B2 (enExample) |
| EP (3) | EP3981420A1 (enExample) |
| JP (4) | JP6673915B2 (enExample) |
| CN (2) | CN107206049B (enExample) |
| AU (1) | AU2015335855A1 (enExample) |
| CA (1) | CA2965325A1 (enExample) |
| DK (2) | DK3209317T3 (enExample) |
| ES (2) | ES2904492T3 (enExample) |
| FI (1) | FI3978074T3 (enExample) |
| HR (1) | HRP20220225T1 (enExample) |
| HU (1) | HUE058066T2 (enExample) |
| PL (2) | PL3209317T3 (enExample) |
| PT (2) | PT3978074T (enExample) |
| SI (1) | SI3209317T1 (enExample) |
| WO (1) | WO2016065117A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20170929T1 (hr) | 2008-09-17 | 2017-09-22 | Chiasma Inc. | Farmaceutski pripravci i odgovarajući postupci za isporuku |
| US20200046798A1 (en) * | 2014-10-24 | 2020-02-13 | Mallinckrodt Hospital Products IP Limited | Method of treating patients with hepatorenal syndrome type 1 |
| US20210290725A1 (en) * | 2014-10-24 | 2021-09-23 | Mallinckrodt Pharmaceuticals Ireland Limited | Method of treating patients with hepatorenal syndrome type 1 |
| JP6673915B2 (ja) * | 2014-10-24 | 2020-03-25 | マリンクロット ホスピタル プロダクツ アイピー リミテッド | １型肝腎症候群患者の治療方法 |
| EP3528828B1 (en) * | 2016-10-21 | 2025-01-29 | Amryt Endo, Inc. | Terlipressin composition for use in treating ascites |
| KR20220011697A (ko) | 2019-05-22 | 2022-01-28 | 바이오비에 아이앤씨. | 테를리프레신 제형 |
| CN110251469B (zh) * | 2019-07-31 | 2021-11-09 | 南京康舟医药科技有限公司 | 一种醋酸特利加压素制剂及其制备方法 |
| WO2021084483A1 (en) * | 2019-10-30 | 2021-05-06 | Mallinckrodt Hospital Products IP Unlimited Company | Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure |
| WO2023183339A1 (en) * | 2022-03-22 | 2023-09-28 | Ocelot Bio, Inc. | Selective vasopressin receptor agonist for end-stage liver disease |
| US20240156895A1 (en) * | 2022-10-28 | 2024-05-16 | Mallinckrodt Pharmaceuticals Ireland Limited | Compositions for improving kidney function in patients with hepatorenal syndrome |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1188443A1 (en) | 2000-09-15 | 2002-03-20 | Ferring BV | Improved protocol for paracentesis |
| US7785857B2 (en) * | 2006-08-31 | 2010-08-31 | Saint Louis University | Protein C variant |
| GB0617581D0 (en) * | 2006-09-07 | 2006-10-18 | Ucl Business Plc | Biomarkers for assessing liver function |
| US20080221551A1 (en) * | 2007-03-09 | 2008-09-11 | Flowmedica, Inc. | Acute kidney injury treatment systems and methods |
| US9050286B2 (en) | 2007-08-14 | 2015-06-09 | Ferring B.V. | Use of peptidic vasopression receptor agonists |
| EP2913676A1 (en) * | 2008-11-10 | 2015-09-02 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| ES2661310T3 (es) | 2009-03-09 | 2018-03-28 | Bioatla, Llc | Proteínas mirac |
| AU2010258888B2 (en) | 2009-06-08 | 2014-08-07 | Ocera Therapeutics, Inc. | Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate |
| AU2011279144A1 (en) * | 2010-07-14 | 2013-01-24 | Cumberland Emerging Technologies, Inc | Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-A2 receptor antagonists |
| JP2012159356A (ja) * | 2011-01-31 | 2012-08-23 | Mochida Pharmaceut Co Ltd | 敗血症診断用組合せマーカー |
| CN103254295A (zh) * | 2013-05-31 | 2013-08-21 | 青岛国大生物制药股份有限公司 | 特利加压素的制备方法 |
| JP6673915B2 (ja) * | 2014-10-24 | 2020-03-25 | マリンクロット ホスピタル プロダクツ アイピー リミテッド | １型肝腎症候群患者の治療方法 |
| JP2017014206A (ja) | 2015-06-30 | 2017-01-19 | ナノアンティバイオティクス，インコーポレイテッド | 腹水の治療 |
-
2015
- 2015-10-22 JP JP2017521988A patent/JP6673915B2/ja active Active
- 2015-10-22 US US14/920,392 patent/US10335452B2/en active Active
- 2015-10-22 ES ES15791430T patent/ES2904492T3/es active Active
- 2015-10-22 SI SI201531790T patent/SI3209317T1/sl unknown
- 2015-10-22 ES ES21205752T patent/ES2987577T3/es active Active
- 2015-10-22 PT PT212057525T patent/PT3978074T/pt unknown
- 2015-10-22 DK DK15791430.0T patent/DK3209317T3/da active
- 2015-10-22 HR HRP20220225TT patent/HRP20220225T1/hr unknown
- 2015-10-22 DK DK21205752.5T patent/DK3978074T3/da active
- 2015-10-22 PT PT157914300T patent/PT3209317T/pt unknown
- 2015-10-22 CN CN201580062745.3A patent/CN107206049B/zh active Active
- 2015-10-22 CN CN202111342532.XA patent/CN114028536B/zh active Active
- 2015-10-22 EP EP21208813.2A patent/EP3981420A1/en active Pending
- 2015-10-22 CA CA2965325A patent/CA2965325A1/en not_active Abandoned
- 2015-10-22 PL PL15791430T patent/PL3209317T3/pl unknown
- 2015-10-22 EP EP21205752.5A patent/EP3978074B1/en active Active
- 2015-10-22 WO PCT/US2015/056861 patent/WO2016065117A1/en not_active Ceased
- 2015-10-22 EP EP15791430.0A patent/EP3209317B1/en active Active
- 2015-10-22 HU HUE15791430A patent/HUE058066T2/hu unknown
- 2015-10-22 FI FIEP21205752.5T patent/FI3978074T3/fi active
- 2015-10-22 AU AU2015335855A patent/AU2015335855A1/en not_active Abandoned
- 2015-10-22 PL PL21205752.5T patent/PL3978074T3/pl unknown
-
2019
- 2019-05-14 US US16/411,944 patent/US20190328831A1/en not_active Abandoned
- 2019-08-28 JP JP2019155678A patent/JP6989571B2/ja active Active
-
2021
- 2021-06-21 JP JP2021102221A patent/JP7346494B2/ja active Active
-
2022
- 2022-09-14 JP JP2022146052A patent/JP2022171795A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017534618A5 (enExample) | ||
| Cairo et al. | Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation | |
| Strippoli et al. | Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease | |
| JP6989571B2 (ja) | １型肝腎症候群患者の治療方法 | |
| Grünig et al. | Safety, tolerability and clinical effects of a rapid dose titration of subcutaneous treprostinil therapy in pulmonary arterial hypertension: a prospective multi-centre trial | |
| Fedorak et al. | VSL3 probiotic mixture induces remission in patients with active ulcerative colitis | |
| JP2025519492A (ja) | 血友病ａ及びｂの処置のためのフィツシラン | |
| Nishijima et al. | Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin | |
| CN114786662A (zh) | 鸟氨酸苯乙酸盐用于治疗高氨血症的剂量和用途 | |
| JP2023113870A (ja) | Ｂ因子阻害剤の使用方法 | |
| JP2006502231A5 (enExample) | ||
| Jakacki et al. | Dose‐intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas | |
| Espinosa et al. | A Case Report of a Young Female With Renal Infarction Secondary to Breakthrough COVID Infection | |
| Bazarbachi et al. | Non-transfusion-dependent thalassaemia: a panoramic survey from pathophysiology to treatment | |
| Modi et al. | WCN25-4211 A COMPARATIVE STUDY OF DESIDUSTAT AND ERYTHROPOIETIN STIMULATING AGENTS IN CKD-RELATED ANEMIA | |
| Kiskaddon et al. | Continuous intravenous sildenafil use, dose titration, tolerability and clinical outcomes in children with pulmonary hypertension. | |
| Sathaporn et al. | A Rare Cause of Refractory Vasodilatory Shock Due to Calcium Channel Blocker Toxicity from Drug-Drug Interaction Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) And Manidipine | |
| Yie et al. | A Case Report of Transfusion-related Acute Lung Injury (TRALI) Type II from A Heathy Male Donor | |
| Lee et al. | The Experience and Management of Two Cases of Metformin-associated Lactic Acidosis | |
| Khalil et al. | Breakthrough Severe COVID-19 Infection After Triple Dose Pfizer Vaccination. | |
| Glezerman | Successful treatment of ifosfamide-induced hyponatremia with AVP receptor antagonist without interruption of hydration for prevention of hemorrhagic cystitis | |
| Curry et al. | Benefit-to-risk profile in the label-specific population of patients with hepatorenal syndrome-acute kidney injury treated with terlipressin | |
| Michael et al. | Relationship of baseline weight and response to lumasiran in patients with primary hyperoxaluria type 1 on hemodialysis | |
| Godin et al. | EVALUATION OF THE INTERACTION BETWEEN DESIPRAMINE ADMINISTERED ORALLY AND COCAINE ADMINISTERED INTRAVENOUSLY IN DOGS | |
| Kaidi et al. | USE OF TELEMETRY IN RATS TO SCREEN KINASE INHIBITORS FOR CARDIOVASCULAR EFFECTS |